SecBot SecBot
DEFA14A ·Filed May 14, 2026

EDAP

EDAP TMS SA
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001104659-26-060707
Proxy solicitation materials
Actionable Insight ▼ Bearish

The filing confirms deteriorating fundamentals and heightened liquidity risk. Expect potential dilutive financing or restructuring announcements. Monitor for drawdown of the remaining €12M EIB tranche and any cost-cutting measures. The annual meeting on June 26, 2026 may include votes on capital authorizations.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$4.13
T+0 close · May 14, 2026 · via day close
Latest settled
+15.50%
T+20 · $4.77
Vs SPY
+16.35%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · May 14 $4.13entry
  2. T+1 · 6mo ago +1.57%α +2.80% · $4.20
  3. T+5 · 6mo ago +4.84%α +5.56% · $4.33
  4. T+20 · 5mo ago +15.50%α +16.35% · $4.77
  5. T+60 · due 3mo ago Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

EDAP TMS SA filed its management report for the 2025 fiscal year ahead of the June 26, 2026 annual general meeting. Consolidated revenue declined 2.7% to €62.4M, while net loss widened to €25.9M from €19.0M, and cash decreased by €9M to €17.4M. The company explicitly warns it needs additional capital and faces going-concern uncertainty.

Key Financial Metrics

Meeting
2026-06-26

Key Facts

  • FY2025 consolidated revenue €62.4M vs €64.1M in 2024 (down ~2.7%)
  • Consolidated net loss widened to €25.9M from €19.0M (36% increase)
  • Operating loss increased to €21.9M from €20.5M
  • Cash and equivalents fell €9M to €17.4M as of Dec 31, 2025
  • Company states it will need significant additional funds and may be unable to continue as a going concern

Financial Impact

Net loss widened by €6.9M YoY; cash burn of €9M; revenue decline of €1.7M

revenuenet incomecashoperating income

Risk Factors

  • Dilutive equity or debt financing likely needed within 12 months
  • Going-concern qualification in future filings if cash runway insufficient
  • Further share price decline on continued losses and no near-term profitability path

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-060707
Document: 0001104659-26-060707-index-headers.html0001104659-26-060707
Document: 0001104659-26-060707-index.html0001104659-26-060707
Document: 0001104659-26-060707.txt0001104659-26-060707

US Market Status

Market Closed · Opens Wed (10h)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026